Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report

• Published in: Biology of blood and marrow transplantation 2018-06, Vol.24 (6), p.1187-1195
• Main Authors: Micallef, Ivana N., Stiff, Patrick J., Nademanee, Auayporn P., Maziarz, Richard T., Horwitz, Mitchell E., Stadtmauer, Edward A., Kaufman, Jonathan L., McCarty, John M., Vargo, Rita, Cheverton, Peter D., Struijs, Martin, Bolwell, Brian, DiPersio, John F.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Child; Granulocyte Colony-Stimulating Factor - therapeutic use; Hematopoietic Stem Cell Mobilization - methods; Hematopoietic Stem Cell Mobilization - mortality; Hematopoietic Stem Cell Transplantation - methods; Heterocyclic Compounds - therapeutic use; Humans; Long-term follow-up; Longitudinal Studies; Lymphoma, Non-Hodgkin - therapy; Middle Aged; Multiple myeloma; Multiple Myeloma - mortality; Multiple Myeloma - therapy; Non-Hodgkin lymphoma; Plerixafor; Stem cell mobilization; Survival Analysis; Transplantation, Autologous - methods; Transplantation, Autologous - mortality; Young Adult
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2018.01.039

•The addition of plerixafor to G-CSF did not affect clinical or long-term safety outcomes.•No differences were noted in 5-year OS/PFS for plerixafor-treated patients.•There was no difference in the composite endpoint of death, progression, and additional treatment. The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.